Context. Toxicity from use of synthetic cannabinoid receptor agonists (SCRAs) has been encountered increasingly frequently in many countries.
Introduction
Synthetic cannabinoid receptor agonists (SCRAs) are increasingly encountered as alternatives to cannabis. [1, 2] They are incorporated into many branded products currently available for purchase from 'head-shops' or via the internet.
[1] These usually consist of plant based material to which SCRAs are added. [1, 3] SCRAs are synthetic modifications to ∆ 9 -tetrahydrocannabinol (∆ 9 -THC), the principal phytocannabinoid occurring in the cannabis plant (Figure 1 ). [4, 5] Like ∆ 9 -THC, they are cannabinoid receptor agonists [6] and have similar pharmacological effects. [7, 8] However, unlike the partial agonist ∆ 9 -THC [1], several SCRAs, such as HU-210 and UR-144, are full cannabinoid receptor agonists [9, 10] and many exhibit an increased binding affinity for both cannabinoid receptors (CB1 and CB2) compared to ∆ 9 -THC. [4, 5, 7, 11, 12] This may explain in part the altered pattern of clinical features and increased severity of toxic effects reported after SCRA use such as encephalopathy and seizure, [13] myocardial infarction, [14] acute kidney injury [15] and extreme psychiatric effects. [16] Some SCRAs are also weak monoamine oxidase inhibitors, which may explain apparent serotoninergic effects. [17] Batch to batch and within product variability in SCRA content [18, 19] and the presence of more than one SCRA in some products [20] may also contribute to unpredictable toxic effects.
There is evidence of a significant increase in the number of SCRA users and associated adverse health effects in recent years. [21, 22, 23] The number of calls to poisons centres in the United States (US) indicates a 229% increase in 2015 compared to 2014. [21] Legal measures to control their use have been taken in many countries. In the United Kingdom (UK), early so-called 'first generation' SCRAs, including JWH-018, were controlled in December 2009 [24] and further legislation to control so-called 'second generation' products, including AM2201 and UR-144, was enacted in February 2013. [25] However, subsequent manipulation of the chemical structure of these compounds has resulted in a further ('third') generation of SCRAs that are not currently legally controlled in the UK including PB-22, 5F-PB-22, STS-135 and 5F-AKB-48. [26] Further legislation is planned, but this will be based on a revised generic description rather than chemical structure. [26] While there is some published evidence of the increasing use and toxicity of SCRAs, limited evidence has been published examining the impacts of legal controls on presentations with toxicity or comparing toxicity between individual SCRAs and SCRA products. This study was therefore performed to characterise the patterns of referrals with SCRA-related toxicity to the UK poisons centres, describe the features of toxicity encountered, compare reported clinical features and severity of poisoning between the most commonly used products and examine the impact of legal control measures on enquiry numbers.
Methods
The study used fully anonymised data collected routinely during telephone enquiries to the National Poison Information Service (NPIS). In the UK, use of such data does not require ethical approval. The NPIS, commissioned by the Health Protection Agency until April 2013 and then by Public Health England, provides clinical advice to health professionals across the UK about the management of toxicity, including toxic effects from legal and illegal recreational drugs. The service is provided by four units located in Newcastle, Edinburgh, Cardiff and Birmingham that work together to provide an integrated 24 hour service. Health professionals can access poisons information on-line via the NPIS's TOXBASE website.
Additional telephone advice can be provided by specialists in poisons information who are supported by a consultant clinical toxicologist as required for complex and severe cases.
For this study a list of 378 possible search terms was compiled to capture the names of SCRAs and SCRA-containing products. This was done by searching for product terms associated with SCRAs in the academic literature and the internet including websites provided for drug users and by internet drug suppliers. We also used the website of the Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) project, [27] which was launched in September 2013 and provides details of the analytical content of products sent by drug users from across the UK. To minimise the effects of other recreational or pharmaceutical agents on clinical features and severity of toxicity of SCRA, patients who reported using other agents simultaneously were identified (co-use group) and excluded from analyses of clinical features and poisoning severity.
Chi-square tests were used to compare the severity of poisoning among the most commonly used products. The severity of poisoning with SCRA products overall was also compared before and after the second (February 2013) modification of the Misuse of Drug Act.
Results
The search terms that might indicate SCRA exposure generated 1196 entries. (Table 2 ).
There were inadequate numbers of enquiries before and soon after the Poisoning severity scores were compared for isolated use of the three most common SCRA products (Table 4) . No significant differences were observed comparing 'Black Mamba' with 'Pandora's Box' (p > 0.05). 'Clockwork Orange' was associated with significantly lower poisons severity scores (p = 0.01) compared to 'Pandora's Box', but the total numbers of enquiries were small. A higher proportion of cases involving neurological or general features in 'Clockwork Orange' users compared to 'Pandora's Box' or 'Black Mamba' was observed.
Discussion
These data demonstrate a substantial recent increase in poisons centre enquiries related to SCRA use in the UK, especially between early 2011 and late 2013. These predominantly involve young males, as previously reported in other countries. [30] It is a particular concern that over a third of enquiries involved people less than 18 years of age. SCRAs 5F-PB-22 and 5F-AKB-48, although there was also one sample containing AM-2201.
[27] This suggests that, in response to legal control, suppliers may change the products being sold or the active constituents of popular branded products so that these are no longer affected by the updated legislation.
It is important to consider not only the numbers of enquiries, but also their severity. Legal control could reduce the frequency of severe episodes by reducing availability of substances shown to be associated with acute harms. On the other hand, control of established substances may encourage users to move to newer SCRAs for which there is less experience of use and where toxicity may be greater. We therefore examined the patterns of poisons severity scores by year and also before and after control of second generation products, but found no time-related differences in the proportion of enquiries associated with moderate or severe poisoning (Table 3) .
We also compared clinical features and severity of poisoning between the three most commonly encountered SCRA-containing branded products. Samples of all three products commonly contain 5F-PB-22 and 5F-AKB48, [27] but differences in toxicity could arise from differences in dose as there is no quantitative information available on their SCRA content.
Exposures to 'Clockwork Orange' were associated with a higher proportion of general and neurological features (Table 4) , but moderate or severe toxicity was less common with this product. However, the numbers of enquiries for each product, especially 'Clockwork Orange', were modest so the reliability of these findings is uncertain and further monitoring is needed.
Use of information collected during poisons centre enquiries has important limitations that need to be taken into account in interpretation. The number of enquiries does not reflect directly the number of clinical exposures or hospital presentations as not all of these will be discussed with a poisons centre. Health professionals may rely on other sources for advice, including the NPIS poisons information database TOXBASE, restricting telephone enquiries to more severely poisoned or unusual cases. Conversely, several enquiries may be received about the same case and identification and consolidation of duplicated information using anonymised records may not always be possible. Clinical features reported during enquiries are often incomplete because only the data needed to answer the enquiry may be given.
Although information on other substances used is sought, accurate information may not be reported by the patient or the enquirer, resulting in an underestimate of the numbers using multiple substances. Also, clinical features that occur after the enquiry has been made are usually not captured. Although follow up is attempted, especially for severe cases, this is often unsuccessful and the final outcome may not be known. This may explain the lower incidence of several clinical features in this series compared with others.
Accurate identification of the chemicals involved in episodes of toxicity is challenging because analytical confirmation is not performed in routine clinical practice. This is a particular problem for SCRAs in view of the large range of branded products involved. The chemical content of these can change with time, [35] therefore comparison using cases of exposure across time to brands that appear similar can be misleading.
Although analysis of clinical features and severity excluded those admitting concurrent use of other substances, the possibility that these may be involved and might have contributed to clinical features in some of these cases cannot be excluded.
Conclusions
NPIS data indicate that cases of toxicity associated with SCRA use have increased in the UK and most commonly involve younger males. Some reported clinical features differ from those associated with cannabis use and severe effects may occur, as previously reported.
No clear evidence of an effect of legal control on enquiry numbers or severity was found.
Further research is needed to characterise possible differences in toxicity between different branded products. 
